USPTO serial 79212480
ELANIX
Reviewed by CopyMark Law Group
Reg. 5634868Status 709
- Filing date
- Status date
- Registration date
- Dec 25, 2018
- Examiner
- MAYES, LAURIE ANN
- Law office
- PUBLICATION AND ISSUE SECTION
What this means
This page summarizes the public USPTO record for this serial number, including owners, goods and services, and prosecution history.
Need help with ELANIX?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Lisa M. DuRoss
Lisa M. DuRoss Harness, Dickey & Pierce, PLC5445 Corporate Drive, Suite 200Troy, MI 48098UNITED STATESGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 003 | Cosmetic preparations, namely, preparations for cleaning, protecting and maintaining in good condition various parts of the human and animal body surface; cosmetic preparations for regeneration of the skin and mucous membranes; cosmetic preparations for personal use | SECTION 71 - CANCELLED | — |
| 005 | Pharmaceutical, biological or biotechnological products for curing or treating dermatological, gynecological and orthopedic conditions namely, pharmaceutical preparations for treating dermatological, gynecological and orthopedic conditions; wound dressing containing foetal cell based/derived proteins; protein augmented surfaces for orthopaedic implants, namely, implantable scaffolds comprising living tissue primarily comprised of proteins; wound dressing containing foetal cell based/derived proteins for which the cells were cultured in conditions as to produce these proteins; protein augmented surfaces for orthopaedic implants, namely, implantable scaffolds comprising living tissue primarily comprised of proteins for orthopaedic implants; pharmaceutical, biological or biotechnological preparations, namely, specialty medicated cosmetic creams, wound dressings, implantable scaffolds comprising living tissue for enhancing therapy or maintaining tissue contour, and cell derivatives being stem cells for medical use for tissue regeneration; pharmaceutical, biological or biotechnological preparations for medical use for treatment ofgynecological illnesses; biological or biotechnological preparations for medical use for treatment of orthopedic injuries; Pharmaceutical, biological or biotechnological preparations for medical use for activating cellular functions namely, for treatment of foetal cell derived structural and adhesion proteins to alter immune responses or enhance wound healing, growth supplements for manufacturing of cell therapies | SECTION 71 - CANCELLED | — |
| 009 | Software for medical applications for diagnosing and monitoring tissue healing in dermatology, orthopedics, and gynecology | SECTION 71 - CANCELLED | — |
| 010 | Matrices for wound dressings in the nature of interactive wound dressings primarily composed of non-living tissue for medical use comprising artificial or organically derived but non-living scaffold materials alone or in combination with cells or cell derivatives to protect the skin and heal skin related conditions, burns, ulcers, cuts, and surgical incisions; Matrices for wound dressings in the nature of interactive wound dressings primarily composed of non-living tissue for medical use comprising artificial or organic gels or creams alone or in combination with non-living cell derivatives to protect the skin and heal skin related conditions burns, ulcers, cuts, and surgical incisions; Matrices for tissue regeneration in the nature of implantable dermatology scaffolds comprising artificial or non-living organic materials alone or in combination with cells or cell derivatives for maintaining tissue contour during tissue regeneration; Matrices in the nature of interactive wound dressings primarily composed of non-living tissue for medical use comprising artificial or non-living organic scaffold materials alone or in combination with cells or cell derivatives to protect gynecologic and urologic intimate zones and heal related conditions, lacerations, dryness, and blistering; Matrices in the nature of interactive wound dressings primarily composed of non-living tissue for medical use comprising artificial or organic gels or creams alone or in combination with cells or cell derivatives to protect gynecologic and urologic intimate zones and heal related conditions, lacerations, dryness, and blistering; Matrices for tissue regeneration in the nature of implantable gynecology scaffolds comprising artificial or non-living organic materials alone or in combination with cells or cell derivatives for maintaining tissue contour during tissue regeneration; Matrices for tissue regeneration comprising artificial or non-living organic scaffold materials alone or in combination with cells or cell derivatives to heal bone, cartilage, tendon related conditions, tendinopathies, and fractures; Matrices for tissue regeneration comprising artificial or organic gels or creams alone or in combination with cells or cell derivatives to heal bone, cartilage, tendon related conditions, tendinopathies, and fractures; Matrices for tissue regeneration in the nature of implantable orthopedic scaffolds comprising artificial or non- living organic materials alone or in combination with cells or cell derivatives for maintaining tissue contour during tissue regeneration | SECTION 71 - CANCELLED | — |
| 040 | Custom manufacture of cosmetic preparations, pharmaceutical preparations and/or chemical preparations for use in industry, intermediate and finished formulations, and single constituents; Custom manufacture of biological tissue and of biotechnological products for use in research; Custom manufacture of cosmetics to order and according to customer requirements; Custom manufacture for others of biological production platforms, biotechnology production platforms for protein production, mammalian and human cells for protein production, organoid production for testing purposes, to order and according to customer requirements | SECTION 71 - CANCELLED | — |
| 042 | Scientific research consulting services provided by consultants in the fields of pharmaceutical, biological, biotechnological, medical and cosmetic research, preclinical and safety assessments | SECTION 71 - CANCELLED | — |
| 044 | Medical services and providing of medical information in the medical field; Medical testing and analysis for diagnostic purposes; Medical consultation services provided by consultants relating to pharmaceutical, biological, biotechnological, cosmetic and medical products | SECTION 71 - CANCELLED | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by Elanix Biotechnologies SA
- Other trademarks owned by Elanix Biotechnologies SA
- Other trademarks owned by Elanix Biotechnologies SA
- Other trademarks in Class 003
- Other trademarks in Class 005
- Other trademarks in Class 009
- Other trademarks in Class 010
- Other trademarks in Class 040
- Other trademarks in Class 042
- Other trademarks in Class 044
- Similar marks named ELANIX
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Mar 11, 2026 | INTR | TOTAL INVALIDATION OF REG EXT PROTECTION CREATED | — |
| Jul 11, 2025 | C71T | CANCELLED SECTION 71 | — |
| Dec 25, 2023 | REM3 | COURTESY REMINDER - SEC. 71 (6-YR) E-MAILED | — |
| Jul 11, 2022 | CHAN | APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED | — |
| Jul 11, 2022 | TCCA | TEAS CHANGE OF CORRESPONDENCE RECEIVED | — |
| Jul 11, 2022 | ECDR | TEAS CHANGE OF DOMESTIC REPRESENTATIVES ADDRESS | — |
| Jul 11, 2022 | EWAF | TEAS WITHDRAWAL OF ATTORNEY RECEIVED-FIRM RETAINS | — |
| Jul 11, 2022 | ARAA | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Jul 11, 2022 | REAP | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED | — |
| Jul 11, 2022 | COAR | TEAS CHANGE OF OWNER ADDRESS RECEIVED | — |
| Apr 26, 2019 | FINO | FINAL DECISION TRANSACTION PROCESSED BY IB | — |
| Apr 5, 2019 | FICS | FINAL DISPOSITION NOTICE SENT TO IB | — |
| Apr 5, 2019 | FIMP | FINAL DISPOSITION PROCESSED | — |
| Mar 25, 2019 | FICR | FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB | — |
| Jan 5, 2019 | OPNX | NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB | — |
| Dec 25, 2018 | R.PR | REGISTERED-PRINCIPAL REGISTER | Your trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive. |
| Dec 19, 2018 | OPNS | NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB | — |
| Dec 19, 2018 | OPNR | NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB | — |
| Oct 9, 2018 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Oct 9, 2018 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Oct 6, 2018 | GPNX | NOTIFICATION PROCESSED BY IB | — |
| Sep 19, 2018 | OPNS | NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB | — |
| Sep 19, 2018 | OP2R | NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB | — |
| Sep 19, 2018 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Sep 4, 2018 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Aug 31, 2018 | XAEC | EXAMINER'S AMENDMENT ENTERED | — |
| Aug 31, 2018 | ALIE | ASSIGNED TO LIE | — |
| Aug 31, 2018 | GNEN | NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED | — |
| Aug 31, 2018 | GNEA | EXAMINERS AMENDMENT E-MAILED | — |
| Aug 31, 2018 | CNEA | EXAMINERS AMENDMENT -WRITTEN | — |
| Jun 7, 2018 | NREP | NEW REPRESENTATIVE AT IB RECEIVED | — |
| Mar 1, 2018 | GNFN | NOTIFICATION OF FINAL REFUSAL EMAILED | — |
| Mar 1, 2018 | GNFR | FINAL REFUSAL E-MAILED | A final Office Action (final refusal) means the examining attorney is maintaining at least one refusal and your options are narrower. You can file a response addressing the refusal, appeal to the Trademark Trial and Appeal Board, or let the application abandon. |
| Mar 1, 2018 | CNFR | FINAL REFUSAL WRITTEN | A final Office Action (final refusal) means the examining attorney is maintaining at least one refusal and your options are narrower. You can file a response addressing the refusal, appeal to the Trademark Trial and Appeal Board, or let the application abandon. |
| Feb 14, 2018 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Feb 13, 2018 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Feb 13, 2018 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Sep 1, 2017 | RFNP | REFUSAL PROCESSED BY IB | — |
| Aug 17, 2017 | RFCS | NON-FINAL ACTION MAILED - REFUSAL SENT TO IB | — |
| Aug 17, 2017 | RFRR | REFUSAL PROCESSED BY MPU | — |
| Aug 1, 2017 | RFCR | NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW | — |
| Jul 31, 2017 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Jul 29, 2017 | RFWR | NON-FINAL ACTION (IB REFUSAL) WITHDRAWN FOR REVIEW | — |
| Jul 24, 2017 | RFCR | NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW | — |
| Jul 23, 2017 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Jul 18, 2017 | MAFR | APPLICATION FILING RECEIPT MAILED | — |
| Jul 14, 2017 | DOCK | ASSIGNED TO EXAMINER | — |
| Jul 14, 2017 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Jul 13, 2017 | REPR | SN ASSIGNED FOR SECT 66A APPL FROM IB | — |